Zacks: Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $2.04 Per Share

Zacks: Analysts Anticipate Gilead Sciences, Inc. (GILD) Will Announce Earnings of $2.04 Per Share

Wall Street brokerages forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will announce earnings per share (EPS) of $2.04 for the current quarter, Zacks reports. Five analysts have made estimates for Gilead Sciences’ earnings. The lowest EPS estimate is $1.87 and the highest is $2.17. Gilead Sciences reported earnings of $3.03 per share during the same quarter last year, which would indicate a negative year over year growth rate of 32.7%. The firm is expected to announce its next earnings results on Monday, July 24th.

According to Zacks, analysts expect that Gilead Sciences will report full-year earnings of $7.88 per share for the current year, with EPS estimates ranging from $6.86 to $8.31. For the next fiscal year, analysts anticipate that the company will post earnings of $7.41 per share, with EPS estimates ranging from $6.26 to $8.46. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.66 billion.

GILD has been the topic of several research analyst reports. Cowen and Company reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Friday, January 6th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Gilead Sciences in a research report on Wednesday, January 11th. Goldman Sachs Group Inc reaffirmed a “hold” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research report on Friday, January 13th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $88.00 price objective on shares of Gilead Sciences in a research report on Friday, January 13th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $93.00 price objective on shares of Gilead Sciences in a research report on Saturday, January 14th. Eleven investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $80.67.

Gilead Sciences (NASDAQ:GILD) traded down 0.41% on Monday, reaching $67.80. 5,788,814 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $67.27 and its 200 day moving average price is $71.20. Gilead Sciences has a 12 month low of $65.38 and a 12 month high of $88.85. The company has a market cap of $88.62 billion, a PE ratio of 6.82 and a beta of 1.11.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Stockholders of record on Friday, June 16th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 3.07%. The ex-dividend date of this dividend is Wednesday, June 14th. Gilead Sciences’s payout ratio is 18.91%.

In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $67.18, for a total value of $4,926,510.94. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $214,973,917.42. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $67.48, for a total value of $337,400.00. Following the completion of the transaction, the executive vice president now owns 117,988 shares of the company’s stock, valued at $7,961,830.24. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in GILD. Lombard Odier Transatlantic Limited Partnership boosted its position in shares of Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 500 shares during the last quarter. Hall Laurie J Trustee boosted its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC boosted its position in shares of Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares during the last quarter. Dubuque Bank & Trust Co. boosted its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Finally, Webster Bank N. A. boosted its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. Hedge funds and other institutional investors own 74.19% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment